AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041

Reuters

06-12

AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041

AIM ImmunoTech Inc. announced the granting of U.S. patent No. 12312376, titled "Therapeutic Double Stranded RNA and Methods for Producing the Same." The patent, which expires on January 25, 2041, covers methods for manufacturing therapeutic double-stranded RNA products, including Ampligen®. This new patent enhances AIM's intellectual property portfolio, providing extended patent protection for manufacturing Ampligen until 2041. The protection supports AIM's ongoing development efforts for Ampligen as it seeks FDA approval for various medical indications, including cancers, viral diseases, and immune system disorders. AIM's CEO, Thomas K. Equels, highlighted the patent as a significant milestone in securing the company's global patent portfolio for Ampligen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467400-en) on June 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542133511"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542133511\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542133511?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-12 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542133511","market":"fut","top_or_hot":-1,"title":"AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AIMI\">AIM ImmunoTech Inc.</a> announced the granting of U.S. patent No. 12312376, titled \"Therapeutic Double Stranded RNA and Methods for Producing the Same.\" The patent, which expires on January 25, 2041, covers methods for manufacturing therapeutic double-stranded RNA products, including Ampligen®. This new patent enhances AIM's intellectual property portfolio, providing extended patent protection for manufacturing Ampligen until 2041. The protection supports AIM's ongoing development efforts for Ampligen as it seeks FDA approval for various medical indications, including cancers, viral diseases, and immune system disorders. AIM's CEO, Thomas K. Equels, highlighted the patent as a significant milestone in securing the company's global patent portfolio for Ampligen.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467400-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-12 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AIMI\">AIM ImmunoTech Inc.</a> announced the granting of U.S. patent No. 12312376, titled \"Therapeutic Double Stranded RNA and Methods for Producing the Same.\" The patent, which expires on January 25, 2041, covers methods for manufacturing therapeutic double-stranded RNA products, including Ampligen®. This new patent enhances AIM's intellectual property portfolio, providing extended patent protection for manufacturing Ampligen until 2041. The protection supports AIM's ongoing development efforts for Ampligen as it seeks FDA approval for various medical indications, including cancers, viral diseases, and immune system disorders. AIM's CEO, Thomas K. Equels, highlighted the patent as a significant milestone in securing the company's global patent portfolio for Ampligen.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467400-en) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL3pMlzd:1","article_id":"2542133511","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542133511","pubTimestamp":1749731433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041. AIM ImmunoTech Inc. announced the granting of U.S. patent No. 12312376, titled \"Therapeutic Double Stranded RNA and Methods for Producing the Same.\" The patent, which expires on January 25, 2041, covers methods for manufacturing therapeutic double-stranded RNA products, including Ampligen. This new patent enhances AIM's intellectual property portfolio, providing extended patent protection for manufacturing Ampligen until 2041. The protection supports AIM's ongoing development efforts for Ampligen as it seeks FDA approval for various medical indications, including cancers, viral diseases, and immune system disorders. AIM's CEO, Thomas K. Equels, highlighted the patent as a significant milestone in securing the company's global patent portfolio for Ampligen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD"},"translate_title":"AIM ImmunoTech获得治疗性dsRNA制造方法的美国专利，将Ampligen的保护延长至2041年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"AIM ImmunoTech Secures U.S. Patent for Manufacturing Methods of Therapeutic dsRNA, Extending Ampligen's Protection Until 2041\n    \n\nAIM ImmunoTech Inc. announced the granting of U.S. patent No. 12312376, titled \"Therapeutic Double Stranded RNA and Methods for Producing the Same.\" The patent, which expires on January 25, 2041, covers methods for manufacturing therapeutic double-stranded RNA products, including Ampligen®. This new patent enhances AIM's intellectual property portfolio, providing extended patent protection for manufacturing Ampligen until 2041. The protection supports AIM's ongoing development efforts for Ampligen as it seeks FDA approval for various medical indications, including cancers, viral diseases, and immune system disorders. AIM's CEO, Thomas K. Equels, highlighted the patent as a significant milestone in securing the company's global patent portfolio for Ampligen.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9467400-en) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}